Avid Bioservices reported solid results for Q2 2025, marked by increased revenues and backlog, although these were offset by increased costs. The company also announced an agreement with GHO and Ampersand, expected to close in Q1 2025, providing stockholders with significant cash value.

Avid Bioservices reported a strong first quarter with revenues of $40.2 million and new business signings of $66 million, resulting in a backlog of $219 million. The company maintained its FY2025 revenue guidance of between $160 million and $168 million.

Avid Bioservices reported record fourth-quarter revenue of $43.0 million, the highest in the company's history. The company signed $30 million in net new business, resulting in a backlog of $193 million. New mammalian and cell and gene therapy facilities are fully operational.

Avid Bioservices reported financial results for the third quarter ended January 31, 2024, with revenue of $33.8 million. The company signed $41 million in net new business, resulting in a record high backlog of $206 million. They also completed their expansion program with the grand opening of a cell and gene therapy manufacturing facility.

Avid Bioservices reported Q2 2024 revenue of $25.4 million. The company signed $35 million in net new business orders, resulting in a backlog of $199 million. Fiscal year 2024 revenue guidance was adjusted to $137 to $147 million.

Avid Bioservices reported strong first quarter results with $37.7 million in revenue and a backlog of $189 million. The company's cell and gene therapy facility expansion is on schedule for opening by the end of calendar Q3 2023.

Avid Bioservices reported record-high revenue for both the fourth quarter and the full fiscal year, driven by strong business development and operational execution. The company signed $55 million in net new business orders, resulting in a record-high backlog of $191 million. Revenue guidance for fiscal year 2024 is between $145 million and $165 million.

Avid Bioservices reported strong Q2 results with $34.8 million in revenue and a significant backlog increase. The company is progressing with facility expansions and has increased its revenue guidance for fiscal year 2023 to $145 to $150 million.

Avid Bioservices reported a strong first quarter for fiscal year 2023, with record revenue of $36.7 million and $41 million in new project orders, leading to a record backlog of $157 million. The company's mammalian and cell and gene therapy businesses are expanding as planned.

Avid Bioservices reported strong Q4 2022 results, marked by $31 million in revenue and a record-high backlog of $153 million. The company's facilities and service expansions are progressing as planned, with new cell and gene therapy suites now operational. Revenue guidance for fiscal year 2023 is projected to be between $140 and $145 million.

Avid Bioservices reported a successful third quarter with strong financial and operational performance, including year-over-year growth in revenues, gross margin, net income, and adjusted EBITDA. The company's backlog reached a record high of $140 million, driven by robust new business signings. Avid Bioservices is expanding its capacity and services, including entry into the cell and gene therapy sector, to support further growth.

Avid Bioservices reported a strong second quarter with year-over-year revenue growth, new business wins, and a substantial backlog. The company initiated a strategic expansion into viral vector development and manufacturing services and signed $36 million in new business orders, ending the quarter with a backlog of $120 million.

Avid Bioservices reported a strong first quarter of fiscal year 2022 with increased revenues compared to the prior year period and significant margin improvements due to the efficiencies of their business model. The company signed $23 million in new business orders and ended the quarter with a backlog of $110 million. They are on track to achieve their full year fiscal 2022 revenue guidance of between $115 million and $117 million.

Avid Bioservices reported a strong Q4 and fiscal year 2021, with revenue reaching $27.6 million for the quarter and $95.9 million for the year. The company achieved operational profitability for four consecutive quarters and signed significant new business orders, resulting in a substantial year-end backlog.

Avid Bioservices reported an exceptional third quarter with strong top-line revenue growth, improved margins, and cash generation. The company signed $74 million in new business, resulting in a record backlog of $120 million. Revenue guidance for fiscal year 2021 was raised to $88 to $91 million.

Avid Bioservices reported strong Q2 results, driven by growth in customer demand, achieving higher-than-expected revenues and margins, and generating operating cash flow and income from operations. The company is raising revenue guidance for fiscal 2021 from between $76 and $81 million to between $84 and $88 million.

Avid Bioservices reported a strong start to fiscal year 2021, achieving revenues of $25.4 million and net income of $4.7 million. The company signed three new customers and project expansion orders with current customers for $20 million, ending the quarter with a backlog of $60 million.

Avid Bioservices reported a productive fourth quarter with higher than anticipated revenues driven by project expansion orders with existing customers. The company ended the year with a strong backlog and strengthened its management team with the appointment of a new CEO and senior directors.

Avid Bioservices reported a third quarter with revenue of $13.6 million. The company faced production challenges due to a specific equipment issue, leading to terminated and postponed manufacturing runs. As a result, the company adjusted its fiscal year 2020 revenue guidance to $55 - $59 million.